Abstract 283P
Background
Bone fracture is a devastating event in patients with mCRC. Nevertheless, no study has compared OF and PF in these patients.
Methods
We retrospectively analyzed clinical data of patients with mCRC who underwent palliative first-line oxaliplatin or irinotecan backbone chemotherapy at Seoul National University Bundang Hospital. This study aimed to identify the cumulative incidence rates of OF and PF in these patients and their risk factors.
Results
A total of 622 patients (male, 359) were consecutively enrolled between Jan. 2008 and Dec. 2015. The median age was 61 years (range, 20-91 years). Before palliative first-line chemotherapy (oxaliplatin backbone and irinotecan backbone in 313 [50.3%] and 309 [49.7%] patients, respectively), the median body mass index was 22.6 kg/m2 (range, 13.8-36.2 kg/m2) and bone metastasis was found in 42 patients (6.8%). During a median follow-up of 65.5 months (range 1.6-126.0 months), the median overall survival was 27.2 months (95% confidence interval [CI], 24.5-29.9 months). Among 81 patients (13.0%) who experienced OF or PF events, OF, PF, and both developed in 42 (6.8%), 36 (5.8%), and 3 (0.5%) patients, respectively. The cumulative incidence rates of OF and PF were 3.4% (95% CI, 2.2-5.0%) and 2.7% (95% CI, 1.7-4.3%) at 1 year, 4.5% (95% CI, 3.1-6.4%) and 4.2% (95% CI, 2.8-6.0%) at 2 years, and 5.6% (95% CI, 3.9-7.6%) and 5.1% (95% CI, 3.5-7.0%) at 3 years, respectively. The cumulative incidence rate of the first OF or PF was 6.0% (95% CI, 4.3-8.0%) at 1 year, 8.6% (95% CI, 6.6-11.0) at 2 years, and 10.4% (95% CI, 8.2-13.0%) at 3 years. The most common fracture sites were the lumbar spines (52.4%) in OF and the thoracic spines (50.0%) in PF, respectively. The OF risk was significantly higher in patients with age ≥ 65 years (hazard ratio [HR] 3.20 [95% CI, 1.73-5.92], p<0.001) while the PF risk was not significant between the age groups (HR 0.77 [95% CI, 0.40-1.49], p=0.430).
Conclusions
Fracture events were substantial in patients with mCRC who received palliative chemotherapy. Notably, the incidence of OF was comparable with that of PF. Therefore, OF should be considered in elderly patients with lumbar spine fractures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
303P - Long-term oncologic outcomes for patients undergoing volatile versus intravenous anesthesia for non-small cell lung cancer surgery
Presenter: Ji Hyung Hong
Session: Poster viewing 04
306P - Multimodal management and outcomes of stage III non-small cell lung cancer: KINDLE-Egypt analysis
Presenter: Rasha Aboelhassan
Session: Poster viewing 04
307P - Differential expression profiling of transcripts in stage IIIA non-small cell lung cancer (NSCLC) of smokers and non-smokers cases of north India: A geneto-environmental study
Presenter: Archana Mishra
Session: Poster viewing 04
308P - Phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
Presenter: Masanao Nakashima
Session: Poster viewing 04
309P - Pneumonitis and corticosteroid treatment in patients with unresectable non-small cell lung cancer receiving durvalumab consolidation after definitive chemoradiotherapy
Presenter: Saori Murata
Session: Poster viewing 04
311P - Cost-effectiveness of alectinib compared with chemotherapy in first-line treatment for anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer in Thailand
Presenter: Sermsiri Sangroongruangsri
Session: Poster viewing 04
312P - ClinMatch: A clinical trial matching platform that improves trial accessibility among NSCLC patients through comprehensive genomic and clinical profiling
Presenter: Allen Chi Shing Yu
Session: Poster viewing 04
313P - A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression
Presenter: Yongfeng Yu
Session: Poster viewing 04